A Biologics License Application has been submitted to the FDA for treatment with the kidney cancer imaging PET drug product, Zircaix®.

2024 was a year of resilience after a myeloma diagnosis, marked by a return to public speaking, a documentary filming ...

Losing my hair after chemo was devastating, and I struggled to accept how it changed my appearance and self-image.

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in ...

F-DOPA PET−guided, dose-escalated, hypofractionated proton beam therapy led to improved OS in older patients with newly ...

Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic ...

Chemotherapy regimen shows potential to improve survival and reduce need for surgery in patients with muscle-invasive bladder ...

Dr. Richard “Rick" Winneker discussed advice that he would provide to patients faced with a myeloproliferative neoplasm ...

After surviving colon cancer, I reflect on how the lessons from my journey transformed my life and guide me to embrace its ...

Veliparib plus temozolomide did not significantly extend overall survival in patients with newly diagnosed, ...

Chimerix submitted a new drug application to the FDA seeking accelerated approval for dordaviprone to treat patients with ...

The FDA has granted priority review to an NDA for taletrectinib in the treatment of advanced ROS1-positive non–small cell ...